Webinar: Underprediction of Drug Clearance by Aldehyde Oxidase (AO)–Mediated Drug Metabolism: Important Considerations for In Vitro Assessment
We are happy to announce the 2nd webinar in our non-CYP metabolism series! If you have not seen the 1st overview webinar, you may access the recording and slides here.
Aldehyde oxidase (AO) enzyme has gained increasing attention in drug development as one of the alternative approaches to reduce P450-mediated drug metabolism liability. However, clinical failure due to poor prediction of AO-mediated clearance is a major hurdle in development of drugs that are AO substrates… Read More
Register to Receive a Link to the Recording & Slides After the Event (est. Sept. 3rd) with the Form Below:
About the Presenter:
Dr. Pallavi Limaye is a Director in the Scientific Consulting department. Pallavi received her Ph.D. in Toxicology from The University of Louisiana. Dr. Limaye originally joined SEKISUI XenoTech in 2011 as a Research Scientist and served as a study director for in vitro drug metabolism studies. In 2020, she joined SEKISUI XenoTech’s consulting team and provides input on drug-drug interaction study needs for sponsors. Dr. Limaye has published several original research articles in various journals and has also contributed many book chapters in the field of toxicology and liver pathobiology. She is also actively involved in scientific societies and currently serves on the E-Learninig Subcommittee of The American College of Toxicology and is the current President of the Central States regional chapter of The Society of Toxicology.